Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Maastricht University Medical Center, Maastricht, Netherlands



Survival: 5.3 months
   
Toxicity Grade: 3
   
Treatments: Biologic therapy
   
Drugs:
Country: Netherlands
   
City/State/Province: Maastricht
   
Hospital: Maastricht University Medical Center
   
Journal: Link
   
Date: 2/2013

Description:
Patients:
This phase 2 study involved 57 advanced non-small cell lung cancer patients who had previously been treated with platinum-based chemotherapy. Their cancer was classified as having the KRAS mutation. The median patient age was 58.5 years and 28.1% were male.

Treatment:
Patients were treated with the biologic therapy agent called sorafenib.

Toxicities:
The most severe toxicities were of grade 3 and included hand-foot skin reaction, rash, and diarrhea.

Results:
The median overall survival was 5.3 months.

Support:
This study was funded by Bayer Pharmaceuticals.

Correspondence: Dr. Egbert F. Smit; email: ef.smit@vumc.nl

E-mail to a Friend Email Physician More Information